Lior Shaltiel

Lior Shaltiel, PhD, is the Chief Executive Officer of NurExone Biologic, where the focus is on developing innovative treatments for paralysis related to spinal cord injuries using exosomes. Additionally, Lior Shaltiel serves as the Initiator and Head of the BioMed-MBA program at The Hebrew University of Jerusalem, aimed at training future leaders in the biomedical sector. Previous roles include Partner at Hollyhigh International Capital, Head of Research and Development at LipoCure Ltd., and co-founder of the UK Israel HealthTech Forum. Lior Shaltiel's educational background includes a PhD in Molecular Pharmacology and Physiology from Ludwig-Maximilians-Universität München, along with master’s and bachelor’s degrees in Cell Physiology and Chemical Engineering from Ben-Gurion University of the Negev.